PMID- 37946408
OWN - NLM
STAT- MEDLINE
DCOM- 20240415
LR  - 20240417
IS  - 2005-9256 (Electronic)
IS  - 1598-2998 (Print)
IS  - 1598-2998 (Linking)
VI  - 56
IP  - 2
DP  - 2024 Apr
TI  - Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell 
      Lymphoma in Korea.
PG  - 681-687
LID - 10.4143/crt.2023.1042 [doi]
AB  - PURPOSE: Programmed death-1 blockade with pembrolizumab has shown promising 
      activity in relapsed/refractory (R/R) extranodal natural killer/T-cell lymphoma 
      (NKTCL), but studies are limited, with small patient numbers. MATERIALS AND 
      METHODS: Thirteen institutes involved with the Consortium for Improving Survival 
      of Lymphoma, a Korean lymphoma study group, collected the clinical data of 59 
      patients treated with pembrolizumab as salvage therapy between 2016 and 2022. 
      RESULTS: The median age of the patients was 60 years (range, 22 to 87 years), and 
      76.3% had advanced Ann Abor stage disease. Pembrolizumab was given to 35.6%, 
      40.7%, and 23.7% of the patients as second-, third-, and fourth- or higher-line 
      chemotherapy, respectively. The overall response rate was 40.7%, with 28.8% 
      having complete response. The estimated 2-year progression-free survival (PFS) 
      and overall survival rates for all patients were 21.5% and 28.7%, respectively; 
      for responders, the rates were 53.0% and 60.7%, respectively. Although not 
      statistically significant, Eastern Cooperative Oncology Group performance status 
      >/= 2 (hazard ratio [HR], 1.91; 95% confidence interval [95% CI], 0.93 to 3.94; 
      p=0.078) and stage III or IV disease (HR, 2.59; 95% CI, 0.96 to 6.96; p=0.060) 
      were associated with a trend toward shorter PFS in multivariate analysis. Grade 3 
      or 4 adverse events (AEs) were noted in 12 patients (20.3%); neutropenia (10.2%), 
      fatigue (6.8%), and pneumonitis (5.1%) were most common AEs. CONCLUSION: In 
      conclusion, while pembrolizumab had a modest effect on patients with R/R NKTCL, 
      it may be a useful salvage therapy for patients with localized disease and good 
      performance status.
FAU - Lee, Ji Yun
AU  - Lee JY
AD  - Division of Hematology-Oncology, Department of Internal Medicine, Seoul National 
      University Bundang Hospital, Seoul National University College of Medicine, 
      Seongnam, Korea.
FAU - Kwon, Ji Hyun
AU  - Kwon JH
AD  - Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, 
      Korea.
FAU - Hur, Joon Young
AU  - Hur JY
AD  - Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang 
      University College of Medicine, Guri, Korea.
FAU - Yi, Jun Ho
AU  - Yi JH
AD  - Division of Hematology-Oncology, Department of Internal Medicine, Chung-Ang 
      University College of Medicine, Seoul, Korea.
FAU - Lee, Ji Hyun
AU  - Lee JH
AD  - Division of Hematology-Oncology, Department of Internal Medicine, Dong-A 
      University College of Medicine, Busan, Korea.
FAU - Cho, Hyungwoo
AU  - Cho H
AD  - Department of Oncology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, Korea.
FAU - Do, Young Rok
AU  - Do YR
AD  - Department of Internal Medicine, Dongsan Medical Center, Daegu, Korea.
FAU - Jo, Jae-Cheol
AU  - Jo JC
AD  - Department of Hematology and Oncology, Ulsan University Hospital, University of 
      Ulsan College of Medicine, Ulsan, Korea.
FAU - Kang, Hye Jin
AU  - Kang HJ
AD  - Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of 
      Radiological and Medical Sciences, Seoul, Korea.
FAU - Koh, Yougil
AU  - Koh Y
AD  - Department of Internal Medicine, Seoul National University Hospital, Seoul, 
      Korea.
FAU - Lee, Won Sik
AU  - Lee WS
AD  - Department of Internal medicine, Busan Paik Hospital, Inje University College of 
      Medicine, Busan, Korea.
FAU - Lim, Sung Nam
AU  - Lim SN
AD  - Department of Internal Medicine, Haeundae Paik Hospital, Inje University College 
      of Medicine, Busan, Korea.
FAU - Yoon, Sang Eun
AU  - Yoon SE
AD  - Division of Hematology and Oncology, Department of Medicine, Samsung Medical 
      Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
FAU - Kim, Seok Jin
AU  - Kim SJ
AD  - Division of Hematology and Oncology, Department of Medicine, Samsung Medical 
      Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
FAU - Lee, Jeong-Ok
AU  - Lee JO
AD  - Division of Hematology-Oncology, Department of Internal Medicine, Seoul National 
      University Bundang Hospital, Seoul National University College of Medicine, 
      Seongnam, Korea.
LA  - eng
PT  - Journal Article
DEP - 20231110
PL  - Korea (South)
TA  - Cancer Res Treat
JT  - Cancer research and treatment
JID - 101155137
RN  - DPT0O3T46P (pembrolizumab)
RN  - 0 (Antibodies, Monoclonal, Humanized)
SB  - IM
MH  - Humans
MH  - Young Adult
MH  - Adult
MH  - Middle Aged
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal, Humanized/adverse effects
MH  - *Lymphoma
MH  - *Lymphoma, T-Cell/drug therapy
MH  - Republic of Korea
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
PMC - PMC11016643
OTO - NOTNLM
OT  - Efficacy
OT  - Extranodal natural killer/T-cell lymphoma
OT  - Pembrolizumab
OT  - Prognosis
COIS- Conflicts of Interest Conflict of interest relevant to this article was not 
      reported.
EDAT- 2023/11/10 06:45
MHDA- 2024/04/15 06:42
PMCR- 2024/04/01
CRDT- 2023/11/10 01:36
PHST- 2023/09/13 00:00 [received]
PHST- 2023/11/09 00:00 [accepted]
PHST- 2024/04/15 06:42 [medline]
PHST- 2023/11/10 06:45 [pubmed]
PHST- 2023/11/10 01:36 [entrez]
PHST- 2024/04/01 00:00 [pmc-release]
AID - crt.2023.1042 [pii]
AID - crt-2023-1042 [pii]
AID - 10.4143/crt.2023.1042 [doi]
PST - ppublish
SO  - Cancer Res Treat. 2024 Apr;56(2):681-687. doi: 10.4143/crt.2023.1042. Epub 2023 
      Nov 10.